Dr. Flávia Sousa is a Tenure-Track Assistant Professor at the Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen, Netherlands. She holds a background in pharmacy and earned her Ph.D. in Biomedical Sciences from the University of Porto, Portugal. Following her doctoral studies, Dr. Sousa pursued postdoctoral research at Imperial College London, subsequently securing a prestigious Marie Curie MINDED fellowship at the Istituto Italiano di Tecnologia, Italy (2021-2022), and an independent Women-in-Science (WINS) research fellowship from NCCR Bio-inspired Materials at the Adolphe Merkle Institute, Fribourg, Switzerland.

As a drug delivery scientist, Dr. Sousa is at the forefront of developing innovative biological nanotherapies for brain cancer treatment. Her pioneering research focuses on encapsulating anti-angiogenic monoclonal antibodies to enhance their efficacy in treating glioblastoma by normalizing tumor vasculature and the tumor microenvironment. Currently, she is advancing the development of a cancer nanovaccine for glioblastoma using state-of-the-art nanotechnology.

Dr. Sousa's groundbreaking work has led to promising advancements in brain cancer treatment, earning her numerous prestigious international grants, including the Fulbright program, the Marie-Sklodowska-Curie Fellowship, MIT Innovators Under 35, and the Female Science Talents initiative. Over the past five years, she has authored more than 40 publications, received 13 scientific awards from various countries, garnered over 1800 citations, and achieved an H-index of 24.